The present invention relates to dihydroisoxazoles that are useful for
treating cellular proliferative diseases, for treating disorders
associated with KSP kinesin activity, and for inhibiting KSP kinesin. The
invention also relates to compositions which comprise these compounds,
and methods of using them to treat cancer in mammals.